Introduction/Background Leiomyosarcomas (LMSM) is an extremely rare tumor (1% of uterine tumors) with a high mortality rate. LMSM is characterized by a high potential for hematogenous metastasis, and high aggressivity. The histological subtype, tumor spread and patient age have all been recognized as important prognostic variables. However, significant issues about the significance of these elements have arisen recently.

Methodology 22 cases of primary and progressive LMSM patients were analyzed in terms of patient age, TNM and grade, time, and place of recurrence. The histological form was evaluated using WHO standards, and the degree of microscopic malignancy was established using the French Federation of Tumor Centers criteria.

Results Recurrences occur most frequently in the lungs (n=15; 68.2%), with just seven instances (31.8%) having local relapses. The tumor formed intramurally in the vast majority of patients (n=21, 95.5%). SMA expression was consistent across all clinical patients.

The time to recurrence development was 14 months in G3 (50% of cases), 26 months in G2, and 24 months in G3 patients (Cox’s F-Test, Grade - (1/2) F(10, 12)=1.04; p=0.47; Grade - (1/3) F(15, 17) = 2.9; p = 0.016; Grade - (2/3) F(14, 16) = 2.7; p = 0.027).

Conclusion In contrast to previous research, we were unable to discover a link between tumor size and metastasis. We believe that the grades of ULMS do not vary in metastasis or recurring tumor. Low-grade forms do not advance to high-grade forms. Tumor size and patient age are not independent indicators of disease progression; SMA and Desmin expression intensity is an IHC indicators of leiomyoma histogenesis; tumor grade is an independent and the most important prognostic marker in the therapy of LMSC.

Disclosures No interest of Conflict. No funding.